EGF-Induced EMT and Invasiveness in Serous Borderline Ovarian Tumor Cells: A Possible Step in the Transition to Low-Grade Serous Carcinoma Cells?
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
In high-grade ovarian cancer cultures, it has been shown that epidermal growth factor (EGF) induces cell invasion by activating an epithelial-mesenchymal transition (EMT). However, the effect of EGF on serous borderline ovarian tumors (SBOT) and low-grade serous carcinomas (LGC) cell invasion remains unknown. Here, we show that EGF receptor (EGFR) was expressed, that EGF treatment increased cell migration and invasion in two cultured SBOT cell lines, SBOT3.1 and SV40 large T antigen-infected SBOT cells (SBOT4-LT), and in two cultured LGC cell lines, MPSC1 and SV40 LT/ST-immortalized LGC cells (ILGC). However, EGF induced down-regulation of E-cadherin and concurrent up-regulation of N-cadherin in SBOT cells but not in LGC cells. In SBOT cells, the expression of the transcriptional repressors of E-cadherin, Snail, Slug and ZEB1 were increased by EGF treatment. Treatment with EGF led to the activation of the downstream ERK1/2 and PI3K/Akt. The MEK1 inhibitor PD98059 diminished the EGF-induced cadherin switch and the up-regulation of Snail, Slug and ZEB1 and the EGF-mediated increase in SBOT cell migration and invasion. The PI3K inhibitor LY294002 had similar effects, but it could not block the EGF-induced up-regulation of N-cadherin and ZEB1. This study demonstrates that EGF induces SBOT cell migration and invasion by activating EMT, which involves the activation of the ERK1/2 and PI3K/Akt pathways and, subsequently, Snail, Slug and ZEB1 expression. Moreover, our results suggest that there are EMT-independent mechanisms that mediate the EGF-induced LGC cell migration and invasion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, the fallopian tube TME of primary HGSOC tumors is characterized by higher ECM deposition (especially laminin), dysplasia, loss of cellular polarity of fallopian tube epithelial cells, and release of several soluble factors that regulate ROS-induced stress, anoikis, invasion and cell growth (Cheng et al., 2012; Alsina-Sanchis et al., 2016; Huang et al., 2016; Micek et al., 2020).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Cheng et al., 2012
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816 · cited 1×
“Overexpression of HER2 has been shown in high-grade ovarian cancer [30,31].”
BackgroundEpithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
Complex networks orchestrate epithelial–mesenchymal transitions
Thiery, J. P., & Sleeman, J. P. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1835 · Cited by 3,958 · cited 1×
“. However, the transition from epithelial to mesenchymal cell characteristics encompasses a spectrum of inter- and intracellular changes, not all of which are always seen during EMT”
BackgroundTwist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., & Weinberg, R. A. (2004) · Cell · doi:10.1016/j.cell.2004.06.006 · Cited by 3,855 · cited 1×
“Recent studies have shown that Twist and ZEB1 not only repress E-cadherin expression but also induce the expression of N-cadherin [45,46].”
BackgroundERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
Devesa, S. S., Blot, W. J., & Fraumeni, J. F. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981115)83:10<2099::aid-cncr8>3.0.co;2-3 · Cited by 2,101
The epithelial–mesenchymal transition: new insights in signaling, development, and disease
Lee, J. M., Dedhar, S., Kalluri, R., & Thompson, E. W. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200601018 · Cited by 2,019 · cited 1×
“A defining feature of EMT is a reduction in E-cadherin levels and a concomitant induction of N-cadherin”
BackgroundMolecular requirements for epithelial–mesenchymal transition during tumor progression
Huber, M. A., Kraut, N., & Beug, H. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.08.001 · Cited by 1,821 · cited 1×
“. Loss of E-cadherin expression is mainly due to an up-regulation of Snail, Slug, Twist, ZEB1 and other transcription factors that repress E-cadherin”
BackgroundRECEPTORS FOR EPIDERMAL GROWTH FACTOR AND OTHER POLYPEPTIDE MITOGENS
Carpenter, G. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004313 · Cited by 1,281 · cited 1×
“It has been shown that the binding of EGF to EGFR rapidly induces clustering and internalization of the ligandreceptor complexes, ultimately resulting in lysosomal degradation of both EGF and its receptor [21].”
BackgroundShih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology*
Auersperg, N., Wong, A. S. T., Choi, K.-C., Kang, S. K., & Leung, P. C. K. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0422 · Cited by 1,046 · cited 1×
“In the ovary, E-cadherin expression is limited to rare regions such as cuboidal and columnar OSE, where cells resemble metaplastic epithelium [38,39].”
BackgroundOverexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
Berchuck, A., Kamel, A., Whitaker, R. S., Kerns, B. J., Olt, G. J., Kinney, R., Soper, J. T., Dodge, R. K., Clarke‐Pearson, D. L., & Marks, P. J. (1990) · PubMed · Cited by 860
SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation
Ahuja, D., Sáenz-Robles, M. T., & Pipas, J. M. (2005) · Oncogene · doi:10.1038/sj.onc.1209046 · Cited by 557 · cited 3×
“These results suggest that p53/Rb and PP2A may not affect the EGF-induced cell migration and invasion in SBOT and LGC cells.”
Backgroundp53 and its mutants in tumor cell migration and invasion
Muller, P. A. J., Vousden, K. H., & Norman, J. C. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009059 · Cited by 463 · cited 3×
“These results suggest that p53/Rb and PP2A may not affect the EGF-induced cell migration and invasion in SBOT and LGC cells.”
BackgroundOvarian Surface Epithelium: Biology, Endocrinology, and Pathology
Auersperg, N. (2001) · Endocrine Reviews · doi:10.1210/er.22.2.255 · Cited by 439
Self-citationTse, J. C., & Kalluri, R. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21215 · Cited by 370 · cited 1×
“been shown to be regulated by a series of intracellular signaling networks, including ERK1/2, PI3K/Akt, Smads, RhoB and bcatenin [4].”
BackgroundColomiere, M., Ward, A. C., Riley, C., Trenerry, M. K., Cameron-Smith, D., Findlay, J., Ackland, L., & Ahmed, N. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604794 · Cited by 320 · cited 1×
“It has been shown that EGF can induce EMT in ovarian surface epithelium (OSE) and ovarian cancer cells, suggesting that EGF may be involved in ovarian cancer pathogenesis and metastasis [9,10].”
BackgroundEpithelial–mesenchymal transition in ovarian cancer
Vergara, D., Merlot, B., Lucot, J.-P., Collinet, P., Vinatier, D., Fournier, I., & Salzet, M. (2010) · Cancer Letters · doi:10.1016/j.canlet.2009.09.017 · Cited by 305 · cited 1×
“. Many signaling pathways have been reported to be involved in the EMT in ovarian cancer”
BackgroundThe prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer
Bartlett, J., Langdon, S., Simpson, B., Stewart, M., Katsaros, D., Sismondi, P., Love, S., Scott, W., Williams, A., Lessells, A., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.53 · Cited by 211 · cited 2×
“Studies using clinical samples have shown that EGFR is expressed in borderline ovarian tumors [7,14].”
BackgroundAhmed, N., Maines-Bandiera, S., Quinn, M. A., Unger, W. G., Dedhar, S., & Auersperg, N. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00478.2005 · Cited by 207 · cited 4×
“It has been shown that the ERK1/2, p38 MAPK and PI3K/ Akt pathways are involved in EGF-induced EMT [9,22].”
BackgroundInfluentialBypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions
Barr, S., Thomson, S., Buck, E., Russo, S., Petti, F., Sujka-Kwok, I., Eyzaguirre, A., Rosenfeld-Franklin, M., Gibson, N. W., Miglarese, M., et al. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9121-7 · Cited by 197 · cited 1×
“The epithelial growth factor receptor (EGFR) family consists of four members, EGFR (HER1), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4), and has been shown to play an important role in metastasis and tumorigenesis in many types of human cancers [5,6].”
BackgroundEllerbroek, S. M., Halbleib, J. M., Benavidez, M., Warmka, J. K., Wattenberg, E. V., Stack, M. S., & Hudson, L. G. (2001) · PubMed · Cited by 193
Sayan, A. E., Griffiths, T. R., Pal, R., Browne, G. J., Ruddick, A., Yagci, T., Edwards, R., Mayer, N. J., Qazi, H., Goyal, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902042106 · Cited by 192 · cited 1×
“Recent studies have shown that Twist and ZEB1 not only repress E-cadherin expression but also induce the expression of N-cadherin [45,46].”
BackgroundE-cadherin expression in human epithelial ovarian cancer and normal ovary
Sundfeldt, K., Piontkewitz, Y., Ivarsson, K., Nilsson, O., Hellberg, P., Brännströ:m, M., Janson, P.-O., Enerbäck, S., & Hedin, L. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970620)74:3<275::aid-ijc7>3.0.co;2-w · Cited by 180 · cited 1×
“. In humans, OSE has either a flat or a cuboidal appearance. Flat OSE does not express E-cadherin. In the ovary, E-cadherin expression is limited to rare regions such as cuboidal and columnar OSE, where cells resemble metaplastic epithelium”
BackgroundCastellvi, J., Garcia, A., Rojo, F., Ruiz‐Marcellan, C., Gil, A., Baselga, J., & Ramon y Cajal, S. (2006) · Cancer · doi:10.1002/cncr.22195 · Cited by 177 · cited 1×
“. Although the contributions of EGF and EGFR signaling have been described in ovarian cancer, the majority of studies have been performed only on high-grade ovarian cancer cells. In borderline tumors, immunohistochemical studies have shown that EGF and the EGFR are expressed, but there is no difference in EGFR stainin…”
BackgroundSerous borderline tumors of the ovary with noninvasive peritoneal implants
Gershenson, D. M., Silva, E. G., Tortolero-Luna, G., Levenback, C., Morris, M., & Tornos, C. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981115)83:10<2157::aid-cncr14>3.0.co;2-d · Cited by 173 · cited 1×
“Serous borderline ovarian tumors (SBOT) are non-invasive and are considered to be distinct entities that give rise to invasive low-grade serous carcinomas (LGC), which have a relatively poor prognosis when compared to SBOT and are unrelated to high-grade serous carcinomas [13].”
BackgroundO'Neill, C. J., Deavers, M. T., Malpica, A., Foster, H., & McCluggage, W. G. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000166367.68459.7d · Cited by 164
Manne, U., Myers, R. B., Moron, C., Poczatek, R. B., Dillard, S. C., Weiss, H. L., Brown, D., Srivastava, S., & Grizzle, W. E. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970620)74:3<296::aid-ijc11>3.0.co;2-a · Cited by 163
Nielsen, J. S., Jakobsen, E. H., Hølund, B., Bertelsen, K., & Jakobsen, A. K. M. (2004) · International Journal of Gynecological Cancer · doi:10.1111/j.1048-891x.2004.14606.x · Cited by 147
Daraï, É., Scoazec, J., Walker, F., Mlika-Cabanne, N., Feldmann, G., Madélénat, P., & Potet, F. (1997) · Human Pathology · doi:10.1016/s0046-8177(97)90007-1 · Cited by 146 · cited 1×
“Ovarian cancer cells with low E-cadherin expression are more invasive, and the absence of E-cadherin expression in ovarian cancers is predictive of poor survival [11,12].”
BackgroundMolecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges
Shih, I.-M., & Kurman, R. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0755 · Cited by 142
Krall, J. A., Beyer, E. M., & MacBeath, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015945 · Cited by 134 · cited 2×
“pathways, whereas low-affinity EGF binding is required for the activation of the STATs and PLCc1 [42].”
BackgroundVeatch, A. L., Carson, L. F., & Ramakrishnan, S. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910580315 · Cited by 133 · cited 1×
“Ovarian cancer cells with low E-cadherin expression are more invasive, and the absence of E-cadherin expression in ovarian cancers is predictive of poor survival [11,12].”
BackgroundRubin, S. C., Finstad, C. L., Wong, G. Y., Almadrones, L., Plante, M., & Lloyd, K. O. (1993) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(12)90907-2 · Cited by 123
Pohl, G., Ho, C.-L., Kurman, R. J., Bristow, R., Wang, T.-L., & Shih, I.-M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3625 · Cited by 123 · cited 5×
“Medium with 10% FBS (750 ml) was added to the lower chamber and served as a chemotactic agent.”
MethodInfluentialSV40 small T antigen and PP2A phosphatase in cell transformation
Sablina, A. A., & Hahn, W. C. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9116-0 · Cited by 115 · cited 3×
“These results suggest that p53/Rb and PP2A may not affect the EGF-induced cell migration and invasion in SBOT and LGC cells.”
BackgroundImmunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms
Cho, E. Y., Choi, Y., Chae, S. W., Sohn, J. H., & Ahn, G. (2006) · Pathology International · doi:10.1111/j.1440-1827.2006.01925.x · Cited by 96 · cited 1×
“presence of microinvasion in serous borderline tumors [40].”
BackgroundNiikura, H., Sasano, H., Sato, S., & Yajima, A. (1997) · International Journal of Gynecological Pathology · doi:10.1097/00004347-199701000-00010 · Cited by 91 · cited 1×
“Amplifications and overexpression of the EGFR family have been reported in high-grade ovarian cancer and are associated with more aggressive clinical behavior and a poor prognosis [7,8].”
BackgroundCheng, J., Klausen, C., & Leung, P. C. K. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0034 · Cited by 86
Steffensen, K. D., Waldstrøm, M., Andersen, R. F., Olsen, D. A., Jeppesen, U., Knudsen, H. J., Brandslund, I., & Jakobsen, A. K. M. (2008) · International Journal of Oncology · doi:10.3892/ijo.33.1.195 · Cited by 59 · cited 1×
“Studies using clinical samples have shown that EGFR is expressed in borderline ovarian tumors [7,14].”
BackgroundZhou, H., Pon, Y. L., & Wong, A. S. T. (2007) · Endocrinology · doi:10.1210/en.2007-0361 · Cited by 53
Cheng, J.-C., Auersperg, N., & Leung, P. C. K. (2010) · Oncogene · doi:10.1038/onc.2010.486 · Cited by 41 · cited 12×
“1 and SBOT4-LT cells, RT- qPCR analysis showed that EGF treatment down-regulated Ecadherin mRNA levels.”
BackgroundResultInfluentialFarley, J. H., Fuchiuji, S., Darcy, K. M., Tian, C., Hoskins, W. J., McGuire, W. P., Hanjani, P., Warshal, D. P., Greer, B. E., Belinson, J. L., et al. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.02.009 · Cited by 40 · cited 1×
“. However, other studies showed no relationship between HER2 expression and survival among patients with high-grade ovarian cancer”
Cheng, J.-C., Auersperg, N., & Leung, P. C. K. (2011) · Oncogene · doi:10.1038/onc.2011.117 · Cited by 38
An improved assay to quantitate the invasiveness of cells in modified Boyden chambers
Woo, M. M. M., Salamanca, C. M., Minor, A., & Auersperg, N. (2007) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-006-9002-4 · Cited by 37 · cited 1×
“Transwell migration and invasion assay Migration and invasion assays were performed in Boyden chambers with minor modifications [20].”
MethodKuwabara, Y., Yamada, T., Yamazaki, K., Du, W., Banno, K., Aoki, D., & Sakamoto, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00946.x · Cited by 33 · cited 1×
“Reduced expression of E-cadherin in human cancers is associated with metastasis, whereas in high-grade ovarian cancer, forced expression of E-cadherin inhibits tumor metastasis”
Backgroundp53 and HER-2/neu Overexpression in Ovarian Borderline Tumors
Eltabbakh, G. H., Belinson, J. L., KENNEDY, A. W., Biscotti, C. V., Casey, G., & Tubbs, R. R. (1997) · Gynecologic Oncology · doi:10.1006/gyno.1997.4661 · Cited by 32
Woo, M. M. M., Salamanca, C. M., Miller, M. W., Symowicz, J., Leung, P. C. K., Oliveíra, C., Ehlen, T. G., Gilks, C. B., Huntsman, D. D., & Auersperg, N. (2008) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01171.x · Cited by 12 · cited 2×
“1 [15], SV40 LT-infected SBOT (SBOT4-LT) [16] and SV40 LT/ST immortalized LGC (ILGC) [18] cell lines were established in our laboratory.”
BackgroundSV40 early genes induce neoplastic properties in serous borderline ovarian tumor cells
Woo, M. M. M., Salamanca, C. M., Symowicz, J., Stack, M. S., Miller, D. M., Leung, P. C. K., Gilks, C. B., & Auersperg, N. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.06.021 · Cited by 7 · cited 12×
“1 and SBOT4-LT, and two LGC-derived cell lines, MPSC1 and ILGC.”
BackgroundResultInfluential
Cited by
Targeting EMT in cancer: opportunities for pharmacological intervention
Davis, F. M., Stewart, T. A., Thompson, E. W., & Monteith, G. R. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.06.006 · Cited by 361
Rizvi, I., Gurkan, U. A., Tasoglu, S., Alagic, N., Celli, J. P., Mensah, L. B., Mai, Z., Demirci, U., & Hasan, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216989110 · Cited by 234
Mechanism of epithelial‐mesenchymal transition in cancer and its regulation by natural compounds
Ang, H. L., Mohan, C. D., Shanmugam, M. K., Leong, H. C., Makvandi, P., Rangappa, K. S., Bishayee, A., Kumar, A. P., & Sethi, G. (2023) · Medicinal Research Reviews · doi:10.1002/med.21948 · Cited by 229
Augustine, R., Hasan, A., Dalvi, Y. B., Rehman, S. R. U., Varghese, R., Unni, R. N., Yalcin, H. C., Alfkey, R., Thomas, S., & Al Moustafa, A.-E. (2021) · Materials Science and Engineering: C · doi:10.1016/j.msec.2020.111519 · Cited by 158
“patches compared to other patches which could be due to the activation of several cell motility associated genes and resulting epithelial-mesenchymal transition (EMT) [86].”
BackgroundInfluentialClapéron, A., Mergey, M., Ho-Bouldoires, T. H. N., Vignjevic, D. M., Wendum, D., Chrétien, Y., Merabtene, F., Frazao, A., Paradis, V., Housset, C., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.03.033 · Cited by 132
Metadata
- Authors
- Cheng, J.-C., Auersperg, N., & Leung, P. C. K.
- Affiliations
- University of British Columbia (CA)
- University of Central Florida (US)
- Corresponding author
- Leung, Peter C. K.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-03-30
- Volume
- 7
- Issue
- 3
- Pages
- e34071
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3316602
- OpenAlex
- W2013958001
- Cited by
- 66
- References
- 46
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 7 · 2018: 2 · 2017: 4 · 2016: 10 · 2015: 3 · 2014: 13 · 2013: 12 · 2012: 2
- FWCI
- 11.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- epidermal growth factor, epithelial-mesenchymal transition, serous borderline ovarian tumor, low-grade serous carcinoma, cell invasion, cell migration, EGF receptor, E-cadherin, N-cadherin, snails, Slug, ZEB1, ERK signaling, PI3K/Akt signaling, MEK1 inhibition, PD98059
- MeSH terms
- Cell Movement, Chromones, Epidermal Growth Factor, Female, Flavonoids, Humans, Morpholines, Neoplasm Invasiveness, Ovarian Neoplasms, Cadherins, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Cystadenocarcinoma, Serous, Gene Expression Profiling, Cell Line, Tumor, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.